Compositions and methods for enhancing the immunogenicity of antigens
AssigneeThe Trustees of the University of Pennsylvania
InventorsYvonne Paterson, Christian Peters, George Gunn
Life of this patent
Estimating the term…
Abstract
The present invention includes compositions, methods and kits for enhancing the immunogenicity of an antigen via fusion to a Listerial protein. The present invention further encompasses Listeria vaccine strains for enhancing the immunogenicity of an antigen.
Claims19
A Listeria monocytogenes vaccine strain comprising an antigen fused to a truncated ActA protein, wherein said truncated ActA protein consists of amino acids 1-390 of said ActA protein;
- wherein said truncated ActA protein comprises a PEST-like sequence selected from the sequences set forth in SEQ ID No:
- 2-5;
- and wherein said antigen is selected from the group consisting of human papilloma virus (HPV) E6, HPV E7, Her-2/Neu, NY-ESO-1, human telomerase, WT-1, proteinase 3, TRP-2 and PSA antigen.
A method of eliciting an enhanced immune response to an antigen, the method comprising administering to a subject an effective amount of a composition comprising a Listeria monocytogenes vaccine strain comprising said antigen fused to a truncated ActA protein, wherein said truncated ActA protein consists of amino acids 1-390 of said ActA protein;
- and wherein said truncated ActA protein comprises a PEST-like sequence selected from the sequences set forth in SEQ ID No:
- 2-5;
- and wherein said antigen is selected from the group consisting of human papilloma virus (HPV) E6, HPV E7, Her-2/Neu, NY-ESO-1, human telomerase, WT-1, proteinase 3, TRP-2, and PSA antigen.
A Listeria monocytogenes vaccine strain comprising an antigen fused to a PEST-like sequence selected from the group consisting of the sequences set forth in SEQ ID No:
- 2-5, wherein said antigen is selected from human papilloma virus (HPV) E6, HPV E7, Her-2/Neu, NY-ESO-1, human telomerase, WT-1, proteinase 3, TRP-2, and PSA antigen.
A method of eliciting an enhanced immune response to an antigen, the method comprising administering to a subject an effective amount of a composition comprising a Listeria monocytogenes vaccine strain comprising said antigen fused to a PEST-like sequence selected from the group consisting of the sequences set forth in SEQ ID No:
- 2-5, wherein said antigen is selected from human papilloma virus (HPV) E6, HPV E7, Her-2/Neu, NY-ESO-1, human telomerase, WT-1, proteinase 3, TRP-2, and PSA antigen.
Dependencies are inferred from the claim text.